SecBot SecBot
8-K ·Filed Nov 3, 2026

ARDX

ARDELYX, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed14d 1h ago SEC0001437402-26-000058
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue growth continues but at a decelerating pace (19% vs 38% in Q1). The narrowing net loss and strong cash position support pipeline investment. Key catalysts are the ACCEL CIC trial readout in H2 2027 and the new patent extending IP protection to 2041. Monitor payor access dynamics and prescription trends for IBSRELA.

DirectionNeutral
Confidencehigh
Horizonmonths

tenapanor

● Neutral Named in this 8-K
Impact
Phase
Approved (IBS-C and hyperphosphatemia); Phase 3 for CIC
Time to market
Already on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.
Next catalyst
None dated

What to watchTenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.

Price Chart

Loading chart...

Executive Summary

Ardelyx reported Q3 2026 total product revenue of $125.5M, up 19% YoY, driven by IBSRELA growth of 23% to $96.3M. Net loss narrowed to $0.7M from $1.0M a year ago. Full-year 2026 guidance was reiterated: IBSRELA $350-$370M, XPHOZAH $110-$120M, operating expenses below $500M. The company completed enrollment ahead of schedule in the Phase 3 ACCEL trial for CIC, with topline data expected in H2 2027.

Key Financial Metrics

EPS
$0.00
Revenue
$125.5M
est $128.0M · -2.0% · +19.0% YoY
Guidance
$460M-$490M
maintained

Key Facts

  • Q3 2026 total product revenue $125.5M, +19% YoY from $105.5M
  • IBSRELA revenue $96.3M, +23% YoY
  • XPHOZAH revenue $29.2M, +7% YoY
  • Net loss narrowed to $0.7M from $1.0M in Q3 2025
  • Cash and investments $285.3M as of Sep 30, 2026, up from $264.7M at Dec 31, 2025
  • Full-year 2026 guidance reiterated: IBSRELA $350-$370M, XPHOZAH $110-$120M, operating expenses below $500M
  • Phase 3 ACCEL trial for CIC fully enrolled ahead of schedule; topline data expected H2 2027
  • USPTO to issue patent covering commercial formulations of IBSRELA and XPHOZAH, expiring Dec 6, 2041

Financial Impact

Revenue growth of 19% YoY to $125.5M; net loss reduced to $0.7M; cash position strengthened to $285.3M

revenuenet losscash

Segment Breakdown

SegmentRevenueGrowth
IBSRELA$96.3M+23.0%
XPHOZAH$29.2M+7.0%

Risk Factors

  • Revenue growth decelerating from 38% in Q1 to 19% in Q3
  • Company remains unprofitable with cumulative net loss of $55.1M in first nine months of 2026
  • Dependence on IBSRELA for majority of revenue; XPHOZAH growth slowing to 7%
  • Payor access barriers and prior authorization requirements could limit IBSRELA adoption
  • Phase 3 ACCEL trial results are binary and not expected until H2 2027

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437402-26-000058
Document: ardx-20261103.htm0001437402-26-000058
Document: ardx-20260930xexhibit992.htm0001437402-26-000058
Document: 0001437402-26-000058-index-headers.html0001437402-26-000058
Document: 0001437402-26-000058-index.html0001437402-26-000058
Document: 0001437402-26-000058.txt0001437402-26-000058
8-K Data (Synthetic)0001437402-26-000058

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026